報價延遲最少15分鐘:2024/12/25 00:15 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
14.99 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.67/--
|
|
企業價值
1.96B
|
| 資產負債 |
|
每股賬面淨值
1.34
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
59.61M
|
|
每股收益
0.42
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/25 00:15 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. |